Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms GO-VIBRANT
- Sponsors Janssen Research & Development
- 14 Nov 2022 Post Hoc analysis (n=241) evaluating the minimal disease activity (MDA) of golimumab, presented at the ACR Convergence 2022.
- 21 Mar 2022 Results of pooled analysis assessing safety of three studies (NCT00973479, NCT02181673 & NCT02186873) published in the Arthritis Research and Therapy.
- 01 Sep 2021 Results of a post-hoc analysis assessing long-term effects of golimumab on patient-reported outcome measures to determine HRQoL through 1 year in patients with active PsA published in the Clinical Rheumatology